Revenue Breakdown
Composition ()
No data
Revenue Streams
Travere Therapeutics Inc (TVTX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is FILSPARI, accounting for 80.3% of total sales, equivalent to $90.90M. Another important revenue stream is Tiopronin Products. Understanding this composition is critical for investors evaluating how TVTX navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Travere Therapeutics Inc maintains a gross margin of 98.03%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -25.00%, while the net margin is -16.95%. These profitability ratios, combined with a Return on Equity (ROE) of -57.80%, provide a clear picture of how effectively TVTX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, TVTX competes directly with industry leaders such as LQDA and APLS. With a market capitalization of $2.72B, it holds a leading position in the sector. When comparing efficiency, TVTX's gross margin of 98.03% stands against LQDA's 94.16% and APLS's 85.13%. Such benchmarking helps identify whether Travere Therapeutics Inc is trading at a premium or discount relative to its financial performance.
